Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
Condition: Type 2 Diabetes Mellitus Interventions: Drug: Sotagliflozin (SAR439954); Drug: Empagliflozin; Drug: Placebo Sponsor: Sanofi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Fortamet | Jardiance | Metformin | Research